The financials
Crinetics Pharmaceuticals, Inc. by the numbers
Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $25M in Q2 2026 (quarter ended June 30, 2026), up 2336% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $121M. For the full year FY2025, revenue was $7.7M (+641% year on year) and net income −$465M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $25M | $1.0M | +2336% |
| Gross profit | $25M | $1.0M | +2321% |
| Operating income | −$132M | −$129M | n/a |
| Net income | −$121M | −$116M | n/a |
| Diluted EPS | −$1.14 | −$1.23 | n/a |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.1M (+152%)
License And Service grew +4.8% year on year
Segment Latestquarter on quarteryear on year
- License And Service$1.1M$1.1MQoQ +152%year on year +4.8%+152%+4.8%